Antineoplaston Therapy for Pediatric DIPG | Burzynski, Houston

Antineoplaston Therapy Offers Hope for Children with DIPG

Diffuse Intrinsic Pontine Glioma (DIPG) is one of the most aggressive and devastating pediatric brain tumors. Located in the brainstem, it affects critical functions such as breathing, heart rate, and motor skills. Conventional treatment options—primarily radiation therapy—often provide only temporary relief, with very limited impact on long-term survival. Families facing a DIPG diagnosis are confronted with few effective therapies and an urgent need for innovative approaches.

At the forefront of such innovation is Dr. Stanislaw Burzynski at Burzynski Clinic in Houston, Texas. For decades, he and his team have explored alternative, targeted therapies aimed at offering hope where standard treatments fall short. Among these approaches is Antineoplaston therapy, a treatment strategy developed and refined at the Burzynski Clinic that has been evaluated in pediatric patients with recurrent brainstem gliomas, including DIPG.

Understanding Antineoplaston Therapy

Antineoplastons are naturally occurring peptides and amino acid derivatives initially identified for their potential anti-cancer properties. At Burzynski Clinic, Dr. Stanislaw Burzynski has focused on harnessing these compounds to selectively target tumor cells while minimizing toxicity to healthy tissue—a key consideration in pediatric oncology.

The therapy involves the use of Antineoplastons A10 and AS2-1, administered under carefully monitored protocols. Unlike traditional chemotherapy, which broadly attacks dividing cells, Antineoplastons are designed to influence cellular signaling pathways, potentially restoring normal cell regulation and slowing tumor progression. This mechanism has positioned the therapy as a promising option for tumors like DIPG that are notoriously resistant to conventional treatments.

Phase II Study Overview

A pivotal Phase II study, published in Child’s Nervous System in 2014 and authored by Dr. Burzynski and colleagues, evaluated the effects of Antineoplastons A10 and AS2-1 in children with recurrent brainstem gliomas, including DIPG. The study focused on patient responses, survival outcomes, and safety.

Results suggested that some children experienced measurable responses, with reductions in tumor progression and stabilization of disease in select cases. While Antineoplaston therapy is not a guaranteed cure, these findings were significant in a patient population with extremely limited options. Importantly, the study highlighted the therapy’s relatively low toxicity profile, which is crucial for pediatric patients already vulnerable to the harsh effects of conventional cancer treatments.

A Commitment to Innovation

The Burzynski Clinic in Houston has long prioritized developing less toxic, targeted approaches for patients who face the most challenging diagnoses. Dr. Stanislaw Burzynski and his team combine rigorous scientific research with individualized patient care, designing treatment plans that account for the unique needs of each child and family.

This dedication to innovation is reflected not only in clinical studies but in ongoing efforts to refine protocols, monitor outcomes, and ensure the highest standards of safety and efficacy. For families dealing with DIPG, having access to these advanced treatment options provides both a potential therapeutic avenue and a sense of hope in an otherwise daunting diagnosis.

Personalized Care in Pediatric Oncology

At Burzynski Clinic, the approach to pediatric cancer goes beyond the therapy itself. Dr. Stanislaw Burzynski emphasizes a personalized care model, where treatment is paired with continuous monitoring, supportive therapies, and family education. Children and families receive guidance on what to expect during therapy, strategies to manage side effects, and comprehensive support throughout the treatment journey.

By combining advanced therapeutic strategies like Antineoplaston therapy with compassionate, individualized care, Burzynski Clinic ensures that patients are treated as more than just a diagnosis—they are cared for as children with unique needs, goals, and families.

Moving Forward

DIPG remains one of the most challenging pediatric cancers, but therapies such as Antineoplastons represent important progress in expanding available treatment options. Clinical research and experience suggest that targeted, less toxic approaches may offer hope where conventional therapies provide limited benefit. For families exploring additional options, Dr. Stanislaw Burzynski and the team at Burzynski Clinic in Houston, Texas, are available to discuss personalized care plans and innovative treatment approaches designed to support children and their families.